Testing and Genotyping of High-Risk Human Papillomavirus by the cobas HPV Test and the Hybrid Capture 2 High-Risk HPV DNA Test Using Cervical and Vaginal Samples | Zendy

Michael T. Pyne | Zendy; Christian Law | Zendy; David R. Hillyard | Zendy; Robert Schlaberg | Zendy

Open Access

Testing and Genotyping of High-Risk Human Papillomavirus by the cobas HPV Test and the Hybrid Capture 2 High-Risk HPV DNA Test Using Cervical and Vaginal Samples

Author(s) -

Michael T. Pyne,

Christian Law,

David R. Hillyard,

Robert Schlaberg

Publication year - 2014

Publication title -

journal of clinical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.349

H-Index - 255

eISSN - 1070-633X

pISSN - 0095-1137

DOI - 10.1128/jcm.03308-13

Subject(s) - genotyping , human papillomavirus , hybrid capture , cervical cancer , typing , papillomaviridae , cervical cancer screening , virology , medicine , hpv infection , oncology , gynecology , biology , genotype , cancer , cervical intraepithelial neoplasia , genetics , gene

The accurate detection and typing of high-risk human papillomavirus (HPV) are critical for cervical cancer screening. The Hybrid Capture 2 (hc2) and cobas HPV tests showed high agreement for cervical samples (94.4%, κ=0.72, n=693) and moderate agreement for vaginal samples (κ=0.62, n=108). The HPV16 and HPV18 results were highly consistent between the cobas and Linear Array tests (κ≥0.96, n=197). Three hc2-negative vaginal samples were repeatedly invalid by the cobas test due to β-globin control failures, highlighting amplification control benefits. No cross-contamination was detected in a challenge experiment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research